Companies / Health Care
A
Agilent Technologies
Life Sciences Tools & Services
Life Sciences Tools & ServicesAnalysis in progress
In progress
We are decoding this company's strategy and relationships
New analyses are published every weekday. Founding members get them first.
Business at a glance
Operating-health scores describe reported fundamentals on a 0–100 scale. They are not a rating of the stock. How they work
Operating health71
Growth37
Profitability71
Cash generation69
Balance sheet88
Dilution control91
Key ratios and five-year financials
Latest quarter revenue YoY (2026-07-31)8.1%Revenue growth (FY)6.7%Revenue CAGR (3y)0.5%Gross margin52.4%Operating margin21.3%Net margin18.8%Free cash flow margin16.6%R&D / revenue6.5%Stock comp / revenue1.8%Net debt / operating cash flow1.00xCurrent ratio1.96Diluted share count change-2.1%
| Fiscal year ending | FY 2021-10 | FY 2022-10 | FY 2023-10 | FY 2024-10 | FY 2025-10 |
|---|---|---|---|---|---|
| Revenue | $6.3B | $6.8B | $6.8B | $6.5B | $6.9B |
| Gross profit | $3.4B | $3.7B | $3.5B | $3.5B | $3.6B |
| Operating income | $1.3B | $1.6B | $1.4B | $1.5B | $1.5B |
| Net income | $1.2B | $1.3B | $1.2B | $1.3B | $1.3B |
| Operating cash flow | $1.5B | $1.3B | $1.8B | $1.8B | $1.6B |
| Capital expenditure | $188M | $291M | $298M | $378M | $407M |
| Free cash flow | $1.3B | $1.0B | $1.5B | $1.4B | $1.2B |
| R&D | $441M | $467M | $481M | $479M | $455M |
| Stock-based comp | $110M | $125M | $111M | $129M | $128M |
| Buybacks | $788M | $1.1B | $575M | $1.1B | $425M |
| Dividends | $236M | $250M | $265M | $274M | $282M |
| Cash | $1.5B | $1.1B | $1.6B | $1.3B | $1.8B |
| Total debt | $2.7B | $2.8B | $2.7B | $3.4B | $3.4B |
| Equity | $5.4B | $5.3B | $5.8B | $5.9B | $6.7B |
StratGraph publishes general, impersonal research about public companies based on public filings. It is not investment advice, not a recommendation to buy, sell or hold any security, and not tailored to any reader's circumstances. Content may contain errors and may be partly generated with AI tools; verify against the original filings, which are linked. Authors may not trade securities discussed within the window set by our trading policy. Full disclaimer.